Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 10/20 | 0.63 |
| ▸ | RAB9A | P51151 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839950 | 0.85 | SLC2A1 (0.60) | RAB9AMAPTNPC1KDM4ESMN1; SMN2 | |
| SCHEMBL6269930 | 0.84 | XDH (0.68) | XDHTP53RAB9AMAPTNPC1 | |
| SCHEMBL11476904 | 0.83 | RAB9A (0.63) | TP53RAB9AMAPTNPC1KDM4E | |
| SCHEMBL6205500 | 0.83 | XDH (0.71) | XDHTP53RAB9AMAPTNPC1 | |
| SCHEMBL13387475 | 0.81 | TP53 (0.59) | TP53RAB9AMAPTNPC1KDM4E | |
| SCHEMBL1243431 | 0.81 | RAB9A (0.50) | XDHTP53RAB9AMAPTNPC1 | |
| SCHEMBL2077026 | 0.80 | ALDH1A1 (0.67) | TP53RAB9AMAPTNPC1KDM4E | |
| SCHEMBL30034914 | 0.80 | ALDH1A1 (0.67) | TP53RAB9AMAPTNPC1KDM4E | |
| SCHEMBL13087213 | 0.80 | SMN1; SMN2 (0.56) | XDHTP53RAB9AMAPTNPC1 | |
| SCHEMBL6206370 | 0.80 | KDM4E (0.73) | XDHTP53RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2373163-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| EP-1551841-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | XDH 43/4885TP53 608/4885RAB9A 2893/4885 |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | XDH 1540/4885TP53 1255/4885RAB9A 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.